IRIX Quote, Financials, Valuation and Earnings

Cutera has a net margin of -16.69% compared to IRIDEX's net margin of -120.06%. IRIDEX's return on equity of -157.91% beat Cutera's return on equity of --.

IRIDEX has a consensus price target of --, signalling upside risk potential of 14.94%. On the other hand Cutera has an analysts' consensus of -- which suggests that it could grow by 512%. Given that Cutera has higher upside potential than IRIDEX, analysts believe Cutera is more attractive than IRIDEX.

IRIDEX has a beta of 0.812, which suggesting that the stock is 18.837% less volatile than S&P 500. In comparison Cutera has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.313%.

IRIDEX has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cutera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IRIDEX pays -- of its earnings as a dividend. Cutera pays out -- of its earnings as a dividend.

IRIDEX quarterly revenues are $11.6M, which are smaller than Cutera quarterly revenues of $32.5M. IRIDEX's net income of -$1.9M is higher than Cutera's net income of -$39M. Notably, IRIDEX's price-to-earnings ratio is -- while Cutera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IRIDEX is 0.59x versus 0.04x for Cutera. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -16.69% compared to IRIDEX's net margin of 10.05%. IRIDEX's return on equity of -157.91% beat Electromed's return on equity of 15.62%.

IRIDEX has a consensus price target of --, signalling upside risk potential of 14.94%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 11.56%. Given that IRIDEX has higher upside potential than Electromed, analysts believe IRIDEX is more attractive than Electromed.

IRIDEX has a beta of 0.812, which suggesting that the stock is 18.837% less volatile than S&P 500. In comparison Electromed has a beta of 0.285, suggesting its less volatile than the S&P 500 by 71.506%.

IRIDEX has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IRIDEX pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

IRIDEX quarterly revenues are $11.6M, which are smaller than Electromed quarterly revenues of $14.7M. IRIDEX's net income of -$1.9M is lower than Electromed's net income of $1.5M. Notably, IRIDEX's price-to-earnings ratio is -- while Electromed's PE ratio is 41.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IRIDEX is 0.59x versus 4.62x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -16.69% compared to IRIDEX's net margin of -10.5%. IRIDEX's return on equity of -157.91% beat Myomo's return on equity of -84.04%.

IRIDEX has a consensus price target of --, signalling upside risk potential of 14.94%. On the other hand Myomo has an analysts' consensus of $7.04 which suggests that it could grow by 19.42%. Given that Myomo has higher upside potential than IRIDEX, analysts believe Myomo is more attractive than IRIDEX.

IRIDEX has a beta of 0.812, which suggesting that the stock is 18.837% less volatile than S&P 500. In comparison Myomo has a beta of 1.709, suggesting its more volatile than the S&P 500 by 70.858%.

IRIDEX has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IRIDEX pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

IRIDEX quarterly revenues are $11.6M, which are larger than Myomo quarterly revenues of $9.2M. IRIDEX's net income of -$1.9M is lower than Myomo's net income of -$966.4K. Notably, IRIDEX's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IRIDEX is 0.59x versus 9.38x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -16.69% compared to IRIDEX's net margin of -67.31%. IRIDEX's return on equity of -157.91% beat Stereotaxis's return on equity of -108.68%.

IRIDEX has a consensus price target of --, signalling upside risk potential of 14.94%. On the other hand Stereotaxis has an analysts' consensus of -- which suggests that it could grow by 92.31%. Given that Stereotaxis has higher upside potential than IRIDEX, analysts believe Stereotaxis is more attractive than IRIDEX.

IRIDEX has a beta of 0.812, which suggesting that the stock is 18.837% less volatile than S&P 500. In comparison Stereotaxis has a beta of 1.570, suggesting its more volatile than the S&P 500 by 57.046%.

IRIDEX has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IRIDEX pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

IRIDEX quarterly revenues are $11.6M, which are larger than Stereotaxis quarterly revenues of $9.2M. IRIDEX's net income of -$1.9M is higher than Stereotaxis's net income of -$6.2M. Notably, IRIDEX's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IRIDEX is 0.59x versus 7.83x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.